

Singapore's Lucence inks strategic collaboration with Agilus to advance cancer testing services in India

25 February 2025 | News

Lucence's proprietary technology will empower Agilus Diagnostics to expand its oncology capabilities



Agilus Diagnostics, India's largest diagnostic company and Lucence, a global pioneering molecular diagnostics company, have entered into a strategic collaboration to advance cancer diagnostics and personalised medicine in India.

This collaboration will integrate Singapore-based Lucence's cutting-edge molecular testing technologies into Agilus' extensive laboratory network, offering enhanced cancer detection, treatment selection, and monitoring capabilities.

Through this collaboration, Agilus Diagnostics will integrate Lucence's advanced molecular testing solutions into its comprehensive oncology diagnostics portfolio. LiquidHALLMARK is an ultra-sensitive, next-generation sequencing liquid biopsy that analyses circulating tumour DNA (ctDNA) and circulating tumour RNA (ctRNA) for clinically relevant biomarkers across various cancers. LiquidHALLMARK profiles actionable somatic mutations in 80 ctDNA genes and 37 ctRNA fusions.

Lucence's proprietary technology will empower Agilus Diagnostics to expand its oncology capabilities, offering liquid biopsy-based screening for early cancer detection, recurrence monitoring, and therapy personalisation. By integrating these pioneering tests into its extensive network of laboratories, Agilus Diagnostics aims to enhance accessibility of precision oncology across India.

This collaboration aligns with Agilus Diagnostics' mission to harness technological advancements in laboratory medicine, ensuring that Indian patients and healthcare providers have access to world-class diagnostic solutions.